Systemic administration of the neurotensin NTS1-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats

Experimental and Clinical Psychopharmacology

Volumn 22, Issue 6, 2014, Pages 541-547

  Keiser, Ashley A ^a   Matazel, Katelin S ^a   Esser, Melissa K ^a   Feifel, David ^b   Prus, Adam J ^a  

^a NORTHERN MICHIGAN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brown Norway; Learning; Long evans; Memory; Neurotensin

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; N2 (2,6 DIAMINOHEXYL)LYSYLPROLYLTRYPTOPHYL 3 METHYLVALYLLEUCINE ETHYL ESTER; NEUROLEPTIC AGENT; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN TYPE 1 RECEPTOR; NOOTROPIC AGENT; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BROWN NORWAY RAT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; LEARNING; LONG EVANS RAT; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; MENTAL PERFORMANCE; NONHUMAN; RADIAL ARM MAZE TEST; RAT; SPATIAL MEMORY; TRAINING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; LONG TERM MEMORY; MAZE TEST; MEMORY DISORDERS; SHORT TERM MEMORY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; COGNITION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SUBCUTANEOUS; MALE; MAZE LEARNING; MEMORY DISORDERS; MEMORY, LONG-TERM; MEMORY, SHORT-TERM; NEUROTENSIN; NOOTROPIC AGENTS; PYRAZOLES; QUINOLINES; RATS, INBRED BN; RATS, LONG-EVANS; RECEPTORS, NEUROTENSIN; RETENTION (PSYCHOLOGY); SPATIAL MEMORY;

EID: 84910076138     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0037912     Document Type: Article

References (46)

1. Antonelli, T., Ferraro, L., Fuxe, K., Finetti, S., Fournier, J., Tanganelli, S., Tomasini, M. C. (2004). Neurotensin enhances endogenous extracellular glutamate levels in primary cultures of rat cortical neurons: Involvement of neurotensin receptor in NMDA-induced excitotoxicity. Cerebral Cortex, 14, 466-473.
2. Azmi, N., Norman, C., Spicer, C. H., & Bennett, G. W. (2006). Effects of a neurotensin analogue (PD149163) and antagonist (SR142948A) on the scopolamine-induced deficits in a novel object discrimination task. Behavioural Pharmacology, 17, 357-362. doi:10.1097/01.fbp.0000224382.63744.20
3. Binder, E. B., Kinkead, B., Owens, M. J., & Nemeroff, C. B. (2001). Neurotensin and dopamine interactions. Pharmacological Reviews, 53, 453-486.
4. Boules, M., McMahon, B., Warrington, L., Stewart, J., Jackson, J., Fauq, A., Richelson, E. (2001). Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties. Brain Research, 919, 1-11. doi:10.1016/S0006-8993(01)02981-X
5. Conti, L. H., Costill, J. E., Flynn, S., & Tayler, J. E. (2005). Effects of a typical and an atypical antipsychotic on the disruption of prepulse inhibition caused by corticotropin-releasing factor and by rat strain. Behavioral Neuroscience, 119, 1052-1060. doi:10.1037/0735-7044.119.4.1052
6. Conti, L. H., Palmer, A. A., Vanella, J. J., & Printz, M. P. (2001). Latent inhibition and conditioning in rat strains which show differential prepulse inhibition. Behavior Genetics, 31, 325-333. doi:10.1023/A: 1012287527438
7. Cusack, B., Boules, M., Tyler, B. M., Fauq, A., McCormick, D. J., & Richelson, E. (2000). Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Research, 856, 48 -54. doi:10.1016/S0006-8993(99)02363-X
8. Feifel, D., Melendez, G., Murray, R. J., Tina Tran, D. N., Rullan, M. A., & Shilling, P. D. (2008). The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology, 200, 197-203. doi:10.1007/ s00213-008-1197-5
9. Feifel, D., Melendez, G., & Shilling, P. D. (2003). A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology, 28, 651- 653. doi:10.1038/sj.npp.1300083
10. Feifel, D., Melendez, G., & Shilling, P. D. (2004). Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: A potential predictive model for novel antipsychotic effects. Neuropsychopharmacology, 29, 731-738. doi:10.1038/sj.npp.1300378
11. Feifel, D., Mexal, S., Melendez, G., Liu, P. Y., Goldenberg, J. R., & Shilling, P. D. (2009). The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog. Neuropsychopharmacology, 34, 2011-2018. doi:10.1038/npp.2009.15
12. Feifel, D., Reza, T. L., Wustrow, D. J., & Davis, M. D. (1999). Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. The Journal of Pharmacology and Experimental Therapeutics, 288, 710-713.
13. Feifel, D., Shilling, P. D., & Melendez, G. (2011). Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats. Behavioral Neuroscience, 125, 268-272. doi:10.1037/a0022691
14. Ferraro, L., Beggiato, S., Tomasini, M. C., Fuxe, K., Tanganelli, S., & Antonelli, T. (2011). Neurotensin regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor functional activity: An in vivo microdialysis study. Journal of Neuroscience Research, 89, 1618-1626. doi:10.1002/jnr.22686
15. Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophrenia Bulletin, 26, 119 -136. doi:10.1093/ oxfordjournals.schbul.a033430
16. Grimond-Billa, S. K., Norman, C., Bennett, G. W., & Cassaday, H. J. (2008). Selectively increased trace conditioning under the neurotensin agonist PD 149163 in an aversive procedure in which SR 142948A was without intrinsic effect. Journal of Psychopharmacology, 22, 290-299. doi:10.1177/0269881106081528
17. Harvey, P. D., Heaton, R. K., Carpenter Jr., W. T., Green, M. F., Gold, J. M., & Schoenbaum, M. (2012). Functional impairment in people with schizophrenia: Focus on employability and eligibility for disability compensation. Schizophrenia Research, 140, 1-8. doi:10.1016/j.schres.2012.03.025
18. Hertel, P., Olsen, C. K., & Arnt, J. (2002). Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour. European Journal of Pharmacology, 439, 107-111. doi:10.1016/S0014-2999(02)01414-0
19. Holly, E. N., Ebrecht, B., & Prus, A. J. (2011). The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats. European Neuropsychopharmacology, 21, 526-531. doi:10.1016/j.euroneuro.2010.12.004
20. Jomphe, C., Lemelin, P. L., Okano, H., Kobayashi, K., & Trudeau, L. E. (2006). Bidirectional regulation of dopamine D2 and Neurotensin NTS1 receptors in dopamine neurons. European Journal of Neuroscience, 24, 2789-2800. doi:10.1111/j.1460-9568.2006.05151.x
21. Li, J., Chen, C., Chen, C., He, Q., Li, H., Li, J., Dong, Q. (2011). Neurotensin receptor 1 gene (NTSR1) polymorphism is associated with working memory. PLoS One, 6, e17365. doi:10.1371/journal.pone.0017365
22. Meltzer, H. Y. (2004). What's atypical about atypical antipsychotic drugs? Current Opinion in Pharmacology, 4, 53-57. doi:10.1016/j.coph.2003.09.010
23. Meltzer, H. Y., & McGurk, S. R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 25, 233-256. doi:10.1093/oxfordjournals.schbul.a033376
24. Norman, C., Grimond-Billa, S. K., Bennett, G. W., & Cassaday, H. J. (2010). A neurotensin agonist and antagonist decrease and increase activity, respectively, but do not preclude discrete cue conditioning. Journal of Psychopharmacology, 24, 373-381. doi:10.1177/ 0269881108097721
25. Palmer, A. A., Dulawa, S. C., Mottiwala, A. A., Conti, L. H., Geyer, M. A., & Printz, M. P. (2000). Prepulse startle deficit in the Brown Norway rat: A potential genetic model. Behavioral Neuroscience, 114, 374-388. doi:10.1037/0735-7044.114.2.374
26. Parwani, A., Duncan, E. J., Bartlett, E., Madonick, S. H., Efferen, T. R., Rajan, R., Rotrosen, J. P. (2000). Impaired prepulse inhibition of acoustic startle in schizophrenia. Biological Psychiatry, 47, 662-669. doi:10.1016/S0006-3223(99)00148-1
27. Petrie, K. A., Bubser, M., Casey, C. D., Davis, M. D., Roth, B. L., & Deutch, A. Y. (2004). The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat. Neuropsychopharmacology, 29, 1878-1888. doi:10.1038/sj.npp.1300494
28. Pettibone, D. J., Hess, J. F., Hey, P. J., Jacobson, M. A., Leviten, M., Lis, E.V., Zeng, Z. (2002). The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. Journal of Pharmacology and Experimental Therapeutics, 300, 305- 313. doi:10.1124/jpet.300.1.305
29. Prus, A. J., Huang, M., Li, Z., Dai, J., & Meltzer, H. Y. (2007). The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: Potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Brain Research, 1184, 354-364. doi:10.1016/j.brainres.2007.09.092
30. Richelson, E., Fredrickson, P. A., & Boules, M. M. (2005). Neurotensin receptor agonists and antagonists for schizophrenia. The American Journal of Psychiatry, 162, 633-634; author reply 635. doi:10.1176/appi.ajp.162.3.633-b
31. Sarhan, S., Hitchcock, J. M., Grauffel, C. A., & Wettstein, J. G. (1997). Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides, 18, 1223-1227. doi:10.1016/ S0196-9781(97)00145-9
32. Schotte, A., Janssen, P. F., Gommeren, W., Luyten, W. H., Van Gompel, P., Lesage, A. S., Leysen, J. E. (1996). Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology, 124, 57-73. doi:10.1007/BF02245606
33. Shilling, P. D., Melendez, G., Priebe, K., Richelson, E., & Feifel, D. (2004). Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist. Psychopharmacology, 175, 353-359. doi:10.1007/s00213-004-1835-5
34. Shilling, P. D., Richelson, E., & Feifel, D. (2003). The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behavioural Brain Research, 143, 7-14. doi:10.1016/S0166-4328(03)00037-8
35. St-Gelais, F., Jomphe, C., & Trudeau, L.-E. (2006). The role of neurotensin in central nervous system pathophysiology: What is the evidence? Journal of Psychiatry & Neuroscience, 31, 229-245.
36. Szigethy, E., Wenk, G. L., & Beaudet, A. (1988). Anatomical substrate for neurotensin-acetylcholine interactions in the rat basal forebrain. Peptides, 9, 1227-1234. doi:10.1016/0196-9781(88)90186-6
37. Tanganelli, S., Antonelli, T. C., Tomasini, M., Beggiato, S., Fuxe, K., & Ferraro, L. (2012). Relevance of dopamine D2/neurotensin NTS1 and NMDA/neurotensin NTS1 receptor interaction in psychiatric and neurodegenerative disorders. Current Medicinal Chemistry, 19, 304-316. doi:10.2174/092986712803414268
38. Tirado-Santiago, G., Lazaro-Munoz, G., Rodriguez-Gonzalez, V., & Maldonado-Vlaar, C. S. (2006). Microinfusions of neurotensin antagonist SR 48692 within the nucleus accumbens core impair spatial learning in rats. Behavioral Neuroscience, 120, 1093-1102. doi:10.1037/0735-7044.120.5.1093
39. U.S. National Research Council of the National Academies, Division on Earth and Life Studies, Institute for Laboratory Animal Research. (2011). Guide for the care and use of laboratory animals (8th ed.). Washington, DC: National Academies Press.
40. van der Staay, F. J. (1999). Spatial working memory and reference memory of Brown Norway and WAG rats in a holeboard discrimination task. Neurobiology of Learning and Memory, 71, 113-125. doi:10.1006/nlme.1998.3860
41. van der Staay, F. J., & Blokland, A. (1996). Behavioral differences between outbred Wistar, inbred Fischer 344, Brown Norway, and hybrid Fischer 344 × Brown Norway rats. Physiology & Behavior, 60, 97-109. doi:10.1016/0031-9384(95)02274-0
42. van der Staay, F. J., van Nies, J., & Raaijmakers, W. (1990). The effects of aging in rats on working and reference memory performance in a spatial holeboard discrimination task. Behavioral & Neural Biology, 53, 356- 370. doi:10.1016/0163-1047(90)90226-V
43. Wenk, G. L., Markowska, A. L., & Olton, D. S. (1989). Basal forebrain lesions and memory: Alterations in neurotensin, not acetylcholine, may cause amnesia. Behavioral Neuroscience, 103, 765-769. doi:10.1037/ 0735-7044.103.4.765
44. Wolden-Hanson, T. (2006). Mechanisms of the anorexia of aging in the Brown Norway rat. Physiology of Behavior, 88, 267-276.
45. Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology, 8, 457- 472. doi:10.1017/ S146114570500516X
46. Xiao, Z., Cilz, N. I., Kurada, L., Hu, B., Yang, C., Wada, E., Lei, S. (2014). Activation of Neurotensin Receptor 1 Facilitates Neuronal Excitability and Spatial Learning and Memory in the Entorhinal Cortex: Beneficial Actions in an Alzheimer's Disease Model. The Journal of Neuroscience, 34, 7027-7042. doi:10.1523/JNEUROSCI.0408-14.2014